Table 5 Histamine Values in All Patients (Original Units)
From: Intraoperative nerve-specific fluorescence visualization in head and neck surgery: a Phase 1 trial
Cohort | Patient ID | Specimen | Units | Normal Range | Pre-infusion | Day 1 (22 h post-infusion) |
|---|---|---|---|---|---|---|
Dose escalation 100 mg | 101–001 | Plasma | nmol/L | 0–8 | Not done | 85 (H) |
101–002 | Plasma | nmol/L | 0–8 | <8 | Not done | |
101–003 | Plasma | nmol/L | 0–8 | <8 | Not done | |
Dose escalation 200 mg | 101–005 | Plasma | nmol/L | 0–8 | 22 (H) | <8 |
101–006 | Plasma | nmol/L | 0–8 | 68 (H) | 8 | |
101–007 | Plasma | nmol/L | 0–8 | <8 | <8 | |
Dose escalation 400 mg | 101–011 | Plasma | nmol/L | 0–8 | 12 (H) | 36 (H) |
103–004 | Whole blood | nmol/L | 180–1800 | 1418 | <174 (L) | |
103–006 | Whole blood | nmol/L | 180–1800 | 384 | 174 (L) | |
Dose escalation 600 mg | 101–012 | Plasma | nmol/L | 0–8 | 19 (H) | 14 (H) |
101–013 | Plasma | nmol/L | 0–8 | 34 (H) | <8 | |
102–001 | Plasma | ng/mL | 0–1.8 | 1.5 | 1.5 | |
Dose escalation 500 mg | 101–014 | Plasma | nmol/L | 0–8 | 8 | <8 |
103–005 | Whole blood | nmol/L | 180–1800 | 1920 (H) | 534 | |
103–008 | Whole blood | nmol/L | 180–1800 | 1620 | <174 (L) | |
Dose timing 3–5 h | 101–016 | Plasma | nmol/L | 0–8 | 33 (H) | <8 |
102–004 | Plasma | ng/mL | 0–1.8 | <1.5 | 1.5 | |
103–009 | Whole blood | nmol/L | 180–1800 | 1894 (H) | <174 (L) | |
103–010 | Whole blood | nmol/L | 180–1800 | 2624 (H) | 2083 (H) | |
103–011 | Whole blood | nmol/L | 180–1800 | 1264 | 297 | |
103–012 | Whole blood | nmol/L | 180–1800 | 1608 | 489 | |
Dose timing 1–3 h | 101–015 | Plasma | nmol/L | 0–8 | 11 (H) | <8 |
101–017 | Plasma | nmol/L | 0–8 | 10 (H) | <8 | |
101–018 | Plasma | nmol/L | 0–8 | Not done | 12 (H) | |
102–005 | Plasma | ng/mL | 0–1.8 | <1.5 | 2.3 (H) | |
102–007 | Plasma | ng/mL | 0–1.8 | <1.5 | 1.5 | |
103–013 | Whole blood | nmol/L | 180–1800 | 653 | Not done |
